BioCentury
ARTICLE | Clinical News

Santalis starts Phase II of East Indian Sandalwood Oil for atopic dermatitis

May 17, 2017 9:02 PM UTC

The Santalis Pharmaceuticals Inc. subsidiary of Quintis Ltd. (ASX:QIN) began a Phase II trial evaluating twice-daily 5% East Indian Sandalwood Oil cream (EISO, SAN007) for 28 days to treat mild to moderate atopic dermatitis. The double-blind, placebo-controlled, U.S. trial will evaluate safety as the primary endpoint in up to 60 patients. Secondary endpoints include the proportion of patients who achieve an improvement in Investigator Global Assessment (IGA) score, Eczema Area and Severity Index (EASI) score and body surface area affected by atopic dermatitis...

BCIQ Company Profiles

Quintis Ltd.